TUTORIALSNov 18, 2026
Merck shares are trading lower after the company announced the discontinuation of the clinical development program evaluating nemtabrutinib, an investigational, oral, non-covalent Bruton’s tyrosine kinase inhibitor.
By Benzinga Newsdesk
Trade what
you just read.
Apply the analysis on a live or demo account, same execution, no risk on demo.
Your seat at the market is ready.
Open your account in minutes, transparent pricing, fast withdrawals and support that answers.



